Really interesting point on the TTWO chart here- I would not be surprised if it turned up today and reclaimed some yardage.. My Buy Price is roughly $133.75// If the market was stronger and it turned up today I would jump in now but that's not the case.
This is about to turn up today-- TLRY Tilray Brands, Inc.- Anybody like the beer move? $2.84-0.19 (-6.13%)11:59 AM 08/09/23 NASDAQ | $USD | Realtime
Tilray Brands stock price forecast The daily chart shows that the TLRY share price has been in a strong bullish trend in the past few months. The shares bottomed at $1.52 in July and is now hovering at $3. It has moved above the important resistance level at $2.63, the lowest swing in September last year. The 25-day and 50-day moving averages have made a bullish crossover pattern. In price action analysis, this crossover is usually a bullish sign. It has also flipped the key resistance at $2.85 into a support level. This was an important level since it was the highest point on May 9th. Therefore, the shares will likely continue rising in the long term as buyers target the key resistance level at $3.50. The stop-loss of this trade will be at $2.50
Tilray Brands, Inc. (TLRY) $2.85 we are on it--- It could move up fromhere. i have a movie at 2:00 watch this!!! NasdaqGS - NasdaqGS Real Time Price. 2.8280-0.1920 (-6.3576%)
I think I've had Redhook's before. Back in the day. They've been around awhile if I'm correct in my recollections of those days. Not a big fan of those heavy beers anymore though. In this case however, my opinion doesn't matter. Craft beers are pretty popular with the 20-45 demographic. NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands”, “Tilray”, “we” or the “Company”) (Nasdaq | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced that the Company has entered into a definitive agreement to acquire eight beer and beverage brands from Anheuser-Busch (NYSE: BUD). Upon satisfaction of customary closing conditions, Tilray will acquire Shock Top, Breckenridge Brewery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewery, Widmer Brothers Brewing, Square Mile Cider Company, and HiBall Energy. I wonder how they are paying for this. Maybe Bud is taking a stake. I'll have to look it up. I think Constellation still owns a chunk of CGC. For now though, TLRY gets the rare GBA 2 thumbsup. TLRY $2.82
Oppenheimer is very long. Mirati Rockets 33% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit Licensing 04:01 PM ET 08/09/2023 Shares of Mirati Therapeutics (MRTX) rocketed Wednesday after a lung-cancer drug regimen paired with Merck's (MRK) Keytruda proved more effective than using blockbuster medication Keytruda by itself. MRTX stock jumped more than 30% in morning trades. X The news came during a bevy of news updates from Mirati. The biotech company narrowly beat June-quarter expectations. It also announced a $300 million public offering and the departure of Chief Executive David Meeks. Meeks will stay on as a consultant through Oct. 15. In the meantime, former CEO, president and founder Charles Baum will act as the interim CEO. In early trading on today's stock market, MRTX stock charged 33.1% ahead, ending the regular session at 37. MRTX Stock: Mixed Lung Cancer Results While the lung cancer tests boosted MRTX stock, they proved to be mixed. Mirati tested a combination of its drug, adagrasib and Merck's Keytruda in patients with high levels of a protein called PD-L1 in their tumors. Tumor cells can use that protein to hide from the immune system. Keytruda binds to the protein, unveiling the tumor cells to the immune system. So, drugs in this class tend to work better in patients with a higher level of PD-L1 in their tumor cells. But adagrasib, which sells under the brand name Krazati, blocks another protein known to drive cancer. Nearly two-thirds of patients with high levels of PD-L1 — 63% — responded to the combination, Mirati said in a presentation. That's far better than Keytruda alone, which leads to a 39% to 45% response rate. Mirati is now planning to begin a final-phase study before the end of the year. Bearishly for MRTX stock, though, the results were less promising in patients with lower levels of PD-L1. The regimen doesn't appear likely to outperform the standard treatment, a combination of immunotherapy and chemotherapy. Instead, Mirati is adding adagrasib to standard drugs. It hopes to make a decision on whether to move that regimen forward into late-stage testing in the first half of 2024. 10% Of All Cancers The company also unveiled promising results for a drug called MRTX1719. It has the potential to treat a genetic defect associated with about 10% of all cancers, including lung, pancreatic and mesothelioma. A third of patients partially responded to Mirati's treatment. Needham analyst Ami Fadia noted the first generation of drugs in this class generally had lower, single-digit response rates. Further, they were toxic in the blood, limiting how much of the drug patients could receive. Mirati didn't find any dose-limiting toxicities at higher doses. "We believe the stock may start to get credit for MRTX1719, and overall we think the stock trades up today," she said in a note to clients. Fadia has a hold rating on MRTX stock. But Evercore ISI analysts Umer Raffat and Jonathan Miller noted one patient ended treatment due to liver toxicity while another dropped out of the study due to fatigue. Other patients had interruptions in treatment due to nausea and vomiting. "Safety will be critical for these second-generation (drugs) given the scrutiny on first-generation molecules," they said. They have an outperform rating on MRTX stock.